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Introduction
A marked prevalence of cardiovascular diseases including 
arterial hypertension has been frequently reported in patients 
with severe mental illnesses such as schizophrenia (Bresee et al., 
2010; Liao et al., 2011; Nasrallah et al., 2015). The high preva-
lence is followed by a concomitant need for non-pharmacological 
interventions and pharmacological treatment to prevent the 
patients from negative consequences (Hennekens et al., 2005). 
Some researchers reported an association between arterial hyper-
tension, metabolic syndrome conditions and negative symptoms 
of schizophrenia (Sicras-Mainar et al., 2015). A plausible inter-
pretation attributes the underlying sedentary lifestyle and lack of 
physical exercise to the negative symptoms, a key element of 
schizophrenia (Fervaha et al., 2014; Rabinowitz et al., 2012). 
Furthermore, antipsychotic treatment is considered to contribute 
to the relative risk of developing cardiovascular disease in schiz-
ophrenia. In contrast to first-generation antipsychotic agents 
(FGAs), second-generation antipsychotics (SGAs) are regarded 
as less cardiotoxic, but a chronic dopamine D2-receptor blockade 
by an SGA might lead to increased sympathetic tone and 
consequently to hypertension and an increased risk of cardiac 
arrhythmia by abolishing peripheral dopaminergic modulation 
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(Scigliano and Ronchetti, 2013). An indirect mechanism may be 
based upon a drug-induced alteration of metabolic homeostasis 
(Correll et al., 2011) and weight gain may play a mediator role in 
schizophrenia-related hypertension (Goff et al., 2005; Nasrallah 
et al., 2006). Non-pharmacological interventions as well as phar-
macological treatment of metabolic syndrome conditions and 
especially hypertension in patients with schizophrenia may be 
essential in eliminating the excess mortality rate and improve-
ment of life expectancy.
However, the pharmacological treatment of hypertension in 
patients with severe mental illnesses often results in multiple 
drug therapy. Hence, the risk of adverse drug reactions (ADRs) 
and the potential for drug–drug interactions (DDIs) increases 
exponentially (Cadieux, 1989) with an increasing number of 
applied drugs. Therefore predicting a potential DDI is important 
for the safety and tolerability of pharmacotherapy in the clinical 
setting. Inhibition of cytochrome (CYP) metabolism is recog-
nized as one of the most important mechanisms of clinical DDIs 
and may result in serious toxicological consequences, if dosage 
of the substrate is not adjusted (Hiemke et al., 2011). Most of 
the psychotropic drugs are metabolized extensively via CYP 
enzymes (Stingl et al., 2013) and some somatic drugs including 
quinidine, terbinafine or amiodarone, which are classified as 
strong, moderate or weak inhibitors of CYP2D6 according to the 
US Food and Drug Administration classification of in vivo inhib-
itors of CYP2D6 (US Food and Drug Administration, 2014) have 
the potential to cause clinically relevant DDIs. Recently, CYP-
mediated DDI and the understanding of pharmacokinetic DDI 
involving CYP isoenzymes have been acknowledged and several 
tables of drugs as substrates, inhibitors and inducers of drug-
metabolizing CYP enzymes have been published (Hiemke et al., 
2011; US Food and Drug Administration, 2014). However, any 
assessment regarding potential DDIs remains provisional consid-
ering the great number of drugs that have not been investigated 
yet with regard to cytochrome blocking or inducing properties.
Therapeutic drug monitoring (TDM) databases are a valuable 
source for a better understanding of potential pharmacokinetic 
interactions. Here, we investigated whether the antihypertensive 
drugs amlodipine or metoprolol have potential interactions with 
the CYP2D6-mediated risperidone (RIS) metabolism.
RIS, a benzisoxazole derivative, is a second generation antip-
sychotic (SGA) with selective antagonistic properties at recep-
tors serotonin/hydroxytryptamine, HT, 5-HT2 and dopamine (D2) 
(Janssen et al., 1988). RIS has been used effectively in the treat-
ment of schizophrenia and a broad spectrum of other psychiatric 
diseases over the past two decades with a low incidence of 
extrapyramidal symptoms (EPSs) and a lack of anticholinergic 
effects (Chouinard and Arnott, 1993; Leucht et al., 1999; Marder 
et al., 1997). The primary pathway of RIS metabolism is a 
CYP2D6-catalysed 9-hydroxylation and the main active metabo-
lite is 9-hydroxyrisperidone (9-OH-RIS). Minor metabolic path-
ways include an oxidative N-dealkylation and 7-hydroxylation. 
RIS and its metabolites are eliminated via the urine and, to a 
much lesser extent, via the faeces. In vitro findings have revealed 
that CYP3A4 and CYP3A5 might also be involved in the 
9-hydoxylation of RIS (Fang et al., 1999; Xiang et al., 2010; 
Yasui-Furukori et al., 2001). As 9-OH-RIS is pharmacologically 
active, clinicians consider the combined concentration of RIS 
and 9-OH-RIS (active moiety (AM)) as the most relevant meas-
ure. According to the Arbeitsgemeinschaft für Neuropsychop-
harmakologie und Pharmakopsychiatrie (AGNP) consensus 
guidelines, a so-called therapeutic reference range of 20–60 ng/mL 
is suggested for the AM (Hiemke et al., 2011).
Amlodipine is a long-acting dihydropyridine calcium-chan-
nel blocker (CCB) acting primarily as a peripheral vasodilator 
(Faulkner et al., 1986). It is slowly absorbed and extensively 
metabolized in the liver, mainly by CYP3A4 (Kim et al., 2006). 
Amlodipine seems to have an enhanced safety profile in patients 
with concomitant diabetes (Fukao et al., 2011) and there is 
some evidence supporting cardioprotective effects (Kjeldsen 
et al., 2014; Lee et al., 2014). To date, there is no clear evidence 
for CYP inhibiting or inducing properties of amlodipine result-
ing in increased or decreased drug concentrations of concomi-
tantly applied CYP-metabolized drugs except some data about 
inhibitory effects on CYP3A4 mediated metabolism of the 
lipid-altering 3-hydroxy-3-methyl-glutaryl-coenzyme A reduc-
tase (HMG-CoA) reductase inhibitor simvastatin (Son et al., 
2014; US Food and Drug Administration, 2014).
Metoprolol is a cardioselective beta-1-adrenoreceptor blocker 
without intrinsic sympathomimetic activity. Approximately 70–
80% of oral metoprolol is metabolized by CYP2D6 in the liver (Li 
and Wang, 2006). A very recent study by Hefner et al. investigated 
a potential inhibitory effect of metoprolol on the CYP-mediated 
metabolism of venlafaxine (VEN) but found no effect on 
CYP2D6-catalysed formation of O-desmethylvenlafaxine (ODV). 
The lack of differences in plasma concentrations of VEN and 
ODV between the metoprolol group and the control group makes 
it unlikely that metoprolol could have a pharmacokinetic interac-
tion potential via other CYP isoenzymes that are involved in VEN 
metabolism such as CYP3A4 or CYP 2C19, (Hefner et al., 2015).
As data on the inhibitory effects of amlodipine on CYP2D6 
and/or CYP3A4/5 with regard to psychotropic drugs are missing 
and data about the effects of metoprolol remain inconsistent, we 
analysed data from a TDM survey obtained from patients whose 
antipsychotic treatment with RIS was individually optimized 
using TDM to further investigate potential effects of amlodipine 
and metoprolol on CYP2D6 mediated hydroxylation of RIS.
Materials and methods
The study was conducted as cooperation between the Department 
of Psychiatry, Psychotherapy and Psychosomatics of RWTH 
Aachen University Hospital, Aachen, Germany, and the 
Department of Psychiatry and Psychotherapy at the University of 
Regensburg, Germany. A large TDM database containing plasma 
concentrations of RIS and 9-OH-RIS of 1584 patients with a 
broad spectrum of psychiatric diseases (exception: organic men-
tal disorders) was analysed. Data collection took place between 
2006–2015 as part of the clinical routine in different institutions 
as part of the Arbeitsgemeinschaft Arzneimittelsicherheit bei 
psychischen Erkrankungen (AGATE), a cooperation for drug 
safety in the treatment of psychiatric diseases (for details see 
www.amuep-agate.de). The database consists of 1584 samples 
from in- and outpatients who had been treated with RIS. 
Retrospective analysis of clinical data for this study was in 
accordance with the local regulatory authority.
We considered three groups in this naturalistic database; a 
group of adult patients that received RIS as an oral formulation 
without a potentially CYP influencing co-medication (control 
group, R0) (Hiemke et al., 2011; US Food and Drug 
Administration, 2014), a group that was co-medicated with 
amlodipine (RA) and a third group that was co-medicated with 
Paulzen et al. 805
metoprolol (RM). No matching processes for age, diagnoses, 
severity of illness, length or onset of illness were undertaken, and 
information on trough value or steady-state conditions were lack-
ing and could therefore not be considered in the study. Moreover, 
patients under concomitant medication with possible CYP2D6 
inhibitory or CYP3A4 inhibitory or inducing properties were 
also excluded. Samples with missing data of RIS or its metabolite 
were also not included in the analysis.
Statistical analysis
The analysis included mainly the comparison of three study 
groups; a group receiving RIS without CYP enzyme influencing 
co-medication (control group, R0), a group receiving RIS + meto-
prolol (RM) and a group receiving RIS + amlodipine (RA). We 
compared the medians and the distributions of the plasma concen-
tration of RIS, 9-OH-RIS and the AM (RIS+9-OH-RIS) between 
the groups. Further comparisons included the plasma concentra-
tion corrected by the daily dose, the so called ‘concentration-
to-dose ratio’, (C/D), and the ratios of 9-OH-RIS/RIS for 
identification of the metabolizer status. Both were calculated in 
accordance with the AGNP consensus guidelines (Hiemke et al., 
2011). Kolmogorov-Smirnov and the Shapiro-Wilk tests of nor-
mality indicated that the data were not normally distributed. 
Therefore, the non-parametrical Kruskal-Wallis test (K-W) with 
a significance level of 0.05 was conducted. For each comparison 
of the two different groups (RM, RA) with the control group (R0) 
we used the Mann Whitney U test with the same significance 
level. Finally, the Jonckheere-Terpstra test (J-T) was used to fur-
ther assess the different patterns of distribution of the adjusted 
C/D. Statistical analysis was carried out using IBM SPSS 
Statistics version 18.0 (IBM GmbH, Ehningen, Germany).
Results
After exclusion of potentially confounding co-medications, 920 
out of 1584 patients met the inclusion criteria. Data from these 
patients were included in the analysis and were assigned to the 
three groups, RA, RM, and R0. The demographic data of these 
patients are summarized in Table 1. The amlodipine group con-
sists of 27 patients, the metoprolol group of 41 patients, while the 
control group consists of 852 patients.
We conducted comparisons based upon the K-W with a 
nominal significance p<0.05. The K-W detected no differences 
regarding the median daily dosage of RIS (Table 1) between the 
three groups (p=0.708); the mean daily doses for RIS were 4.34 
mg/d, standard deviation (SD)=2.03 in the R0-group, 4.13 mg/d, 
SD=2.39 for RM and 3.9 mg/d, SD=2.07 for RA. Age and gender 
distributions showed significant differences between groups 
(p<0.001 and p=0.005); patients under co-medication with 
amlodipine were older than patients under co-medication with 
metoprolol and control group patients. Furthermore, there were 
more women in the RA-group than in the R0 and the RM (see 
Table 1). The comparison of the distribution (subscript indices 
‘D’) and the medians (subscript indices ‘M’) of the plasma con-
centrations of RIS, 9-OH-RIS, and the AM (RIS+9-OH-RIS) 
between the three groups did not yield any significant differ-
ences (RISD, p=0.062, 9-0H-RISD, p=0.698 and RIS+9-OH-
RISD, p=0.369); RISM (p=0.191; 9-0H-RISM, p=0.898 and 
RIS+9-OH-RISM, p=0.266).
The median plasma concentrations (ng/mL) of RIS, 
9-OH-RIS, the AM (RIS+9-OH-RIS), as well as the metabolic 
ratios (9-OH-RIS/RIS) are displayed in Table 2.
The metabolic ratio (9-OH-RIS/RIS) and the adjusted C/D for 
the active metabolite 9-OH-RIS did not differ between the groups 
(9-OH-RIS/RISD, p=0.059, 9-OH-RIS/RISM, p=0.124; C/D 
9-OH-RISD, p=0.125, C/D 9-OH-RISM, p=0.208).
Table 3 shows the C/Ds (ng/mL/mg), for RIS, 9-OH-RIS and 
RIS+9-OH-RIS for each of the three groups.
The distribution of C/Ds for RIS and for the AM (RIS+9-OH-
RIS) showed significant differences between the three study groups 
(p=0.006 and p=0.005 respectively) as well as the medians of C/D 
for RIS and RIS+9-OH-RIS (p=0.040 and p=0.041) (Figure 1).
Using the J-T to detect the different patterns of distribution of 
the latter parameters (C/D (RIS) and C/D (RIS+9-OH-RIS)), we 
Table 1. Patients’ demographic characteristics.
Group Number Age (years) Gender DD RIS (mg/day)
% Females % Males Median (range)
Amlodipine (RA) 27 61.0 (27-80)a 74.1b 25.9 4.0 (1.00–8.0)
Metoprolol (RM) 41 49.8 (21–87)a 36.6b 63.4 4.0 (1.00–8.0)
Control (R0) 852 41.25 (18–87)a 44.2b 55.8 4.0 (1.00–10.0)
DD: daily dosage; RIS: risperidone.
aAge values in the RA group were significantly higher than in the RM and the control group (p<0.001 for Kruskal-Wallis test).
bGender distributions differed between groups, with female patients being more in the RA group than in the control group and RM (p=0.005 for Kruskal-Wallis test).
Table 2. Median plasma concentrations (range) and metabolic ratios of risperidone (RIS) in the study groups.
Group RIS 9-OH-RIS RIS+9-OH-RIS 9-OH-RIS/RIS
Amlodipine (RA) 5.6 (0.3–67.0) 19.00 (4.5–49.0) 30.50 (6.7–112.0) 2.00 (0.23–56.67)
Metoprolol (RM) 6.7 (0.5–54.0) 17.00 (2.0–48.0) 26.00 (2.8–82.0) 2.90 (0.04–31.0)
Control (R0) 4.4 (0.1–224.0) 17.00 (0.3–196.5) 24.0 (1.8–264.0) 3.8 (0.04–290.0)
9-OH-RIS: 9-hydroxyrisperidone.
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found an ascending trend for the medians of C/D (RIS) and C/D 
(RIS+9-OH-RIS) between R0, RM and RA (standard (std) J-T 
value=3.22, p=0.001 and 3.086, p=0.002), with R0 showing the 
lowest and RA showing the highest values.
A Mann-Whitney U test was used to control for significant 
distribution differences between pairs of groups (R0 vs RA and R0 
vs RM). R0 vs RA revealed significant distribution differences for 
C/D RIS (p=0.025), C/D 9-OH-RIS (p=0.048) and C/D AM 
(p=0.005), with the amlodipine group showing higher values in 
all cases. The metabolic ratios did not differ between R0 and RA 
(p=0.182).
Comparing R0 vs RM yielded no differences regarding the dis-
tribution of C/D for 9-OH-RIS and C/D for AM (p=0.57 and 
p=0.087) while the distribution of C/D RIS significantly differed 
between the two groups (p=0.017), with higher values in the 
metoprolol group. The distribution of the metabolic ratios showed 
a slightly significant difference (p=0.044), with the metoprolol 
group demonstrating significantly lower values.
The distribution differences of C/D RIS and C/D AM between 
the study groups are quintessentially captured in Table 4. In the 
amlodipine group, the number of patients with a ‘higher than the 
median‘ C/D, for the AM, RIS+9-OH-RIS, n=19, was more than 
twice as much as the number of patients having a lower than the 
median C/D (n=8). The median C/D for the AM was significantly 
higher in the amlodipine group (p=0.041). The C/D levels for 
RIS showed a similar pattern in the amlodipine group, so that 
patients with a ‘higher than the median’ C/D (RIS) were twice 
(n=18) as many as the ones with ‘lower than the median’ C/D 
Table 3. Median concentration-to-dose ratios (C/Ds) of risperidone (RIS) in the different groups.
Group C/D RIS C/D 9-OH-RIS C/D RIS+9-OH-RIS
Amlodipine (RA) 2.27 a (0.15–16.75) 5.16 a (1.2–12.25) 9.12 a (2.0–28.0)
Metoprolol (RM) 1.93 b (0.12–27.0) 4.35 (0.58–16.0) 7.25 (0.7–28.0)
Control (R0) 1.16 (0.02–74.67) 4.33 (0.08–42.0) 6.29 (0.5–88.0)
9-OH-RIS: 9-hydroxyrisperidone.
a C/D values for RIS, 9-OH-RIS and RIS+9-OH-RIS in the RA group were significantly higher than in the control group (p=0.025, p=0.048 and p=0.005 for Mann-Whitney U 
Test).
bC/D values for RIS in the RM group were significantly higher than in the control group (p=0.017 for Mann-Whitney U Test).
Table 4. Distribution of frequencies of concentration-to-dose ratios (C/Ds) of risperidone (RIS) and active moiety in the different study groups.
Control Metoprolol Amlodipine
C/D
RIS
>Median 416 26 18
⩽Median 436 15 9
C/D
RIS +9-OH-RIS
>Median 413 24 19
⩽Median 439 17 8
9-OH-RIS: 9-hydroxyrisperidone.
Figure 1. Median concentration-to-dose ratios (C/D) of risperidone (RIS), 9-hydroxyrisperidone (9-OH-RIS) and active moiety in the different 
groups. CI: confidence interval.
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levels (n=9). It should be noted that the C/D (RIS) was signifi-
cantly higher in the amlodipine group (p=0.04).
Discussion
Cardiovascular diseases including arterial hypertension are highly 
prevalent in patients with severe mental disorders such as schizo-
phrenia and the pharmacological treatment may be essential in 
eliminating the excess mortality rate and improving life expectancy 
(Crump et al., 2013; Ringen et al., 2014). By adding antihyperten-
sive and/or cardioprotective drugs to an ongoing antipsychotic 
treatment, the risk of pharmacokinetic DDIs is increasing. To pre-
dict potential DDIs, knowledge about potential CYP450 mediated 
interactions as one source of an increased risk is essential to enhance 
safety and tolerability in the treatment of the psychiatric disease as 
well as in the treatment of the somatic disease. Knowledge about 
metabolic pathways of concomitantly applied drugs and the poten-
tial of any particular drug to induce or inhibit CYP isoenzymes is of 
high clinical importance to prevent the patient from unwanted side 
effects or to prevent the patient from loss of treatment efficacy. Data 
from TDM surveys provide an essential source to better understand 
the effects of polypharmacy in clinical settings (Schoretsanitis et al., 
2016). The primary aim of this study was to compare the potential 
of two co-medications, amlodipine and metoprolol, to inhibit 
CYP2D6 and/or CYP3A4/5 and thereby influence the metabolism 
of an antipsychotic treatment with RIS which is mainly but not 
exclusively metabolized via CYP2D6.
To our knowledge, information about potential pharmacoki-
netic DDIs between amlodipine and RIS as well as between 
metoprolol and RIS is lacking thus far and our findings support 
the notion that the selection of the optimal antihypertensive drugs 
should not only take psychiatric comorbidities into account but 
also concomitant psychotropic medication.
In our naturalistic sample, patients on a stable dose of RIS in 
the control group and patients who were co-medicated with 
amlodipine or metoprolol demonstrated considerably different 
patterns of plasma concentrations of RIS, 9-OH-RIS and AM as 
well as different patterns of C/Ds. While the daily dosage of RIS 
did not differ significantly between the study groups, patients that 
were co-medicated with amlodipine showed significantly higher 
median values for the C/Ds of the parent compound, C/D RIS, the 
active metabolite, C/D 9-OH-RIS and the AM, C/D (RIS+9-OH-
RIS), than patients in the control group. Patients that were co-
medicated with metoprolol showed significantly higher median 
values for C/D RIS while C/D 9-OH-RIS and C/D for the AM did 
not differ from the control group. Furthermore, the distribution of 
the concentration-to-dose ratios showed an interesting pattern in 
the sense that patients in the amlodipine group were twice as 
likely to show C/D levels for RIS and the AM above the median 
as controls. Although pharmacokinetic parameters showed a high 
inter-individual variability, which has been detected in other stud-
ies as well (Balant-Gorgia et al., 1999; Cabaleiro et al., 2015; 
Feng et al., 2008), it should be noted that we observed no addi-
tional distribution differences regarding plasma concentrations 
and metabolic ratios of RIS as well as the C/Ds of the active 
metabolite of RIS (9-OH-RIS) between the groups. To our under-
standing, the findings presented herein imply a potential inhibit-
ing effect of amlodipine most likely on the CYP3A4/5 mediated 
metabolism of RIS, leading to significantly higher median values 
of the concentration-to-dose ratios of RIS, 9-OH-RIS and the AM. 
This hypothesis might be supported by the fact that amlodipine is 
metabolized via CYP3A4 on the one hand and is known to have 
inhibitory effects on CYP3A4 as well. The latter properties have 
been shown to have clinical relevance for plasma concentrations 
of the HMG-CoA reductase inhibitor simvastatin which is used to 
provide cholesterol-lowering effects (Nishio et al., 2005; Son 
et al., 2014). Consequentially, we suggest a moderate inhibiting 
effect of amlodipine on CYP3A4 leading to significantly different 
concentration-to-dose ratios but without significant effects on the 
plasma concentration of RIS and its active metabolite or the AM. 
This effect can have potential clinical implications with regard to 
clinical response and adverse effects (De Leon et al., 2005; Riedel 
et al., 2005), particularly since antipsychotic polypharmacy is 
prevalent (Gallego et al., 2012; Spina and de Leon, 2007) and in 
case of RIS, since 9-OH-RIS is eliminated more slowly which can 
be seen in a longer half-life time and a lower plasma protein bind-
ing than RIS.
As different CYP isoenzymes are involved in the metabolism 
of RIS to its renally excreted active metabolite 9-OH-RIS, the 
pharmacokinetic interaction potential of concomitantly applied 
drugs not only concerning their ability to influence the main met-
abolic pathway via CYP2D6 have to be considered. Hence, 
amlodipine with its impact on downstream metabolic pathways 
of RIS via CYP3A4 is an important example for potential phar-
macokinetic interactions offside the main metabolic pathway.
The co-medication with metoprolol slightly altered the con-
centration of C/D RIS compared with the control group. Patients 
under metoprolol had higher C/D RIS values than the control 
group. However, this increase was not reflected in the C/D for the 
AM, showing no significant difference between the two groups. 
This illustrates a rather slight inhibitory effect of metoprolol on 
RIS metabolism, which was further implied by the lower meta-
bolic ratio in the metoprolol group (p=0.044). This finding should 
be considered in the light of the common metabolic pathway of 
RIS and metoprolol, since they’re both metabolized by CYP2D6. 
To our knowledge, no data have been reported suggesting an 
auto-inhibiting effect of metoprolol. Consequently, one might 
assume a weak effect of metoprolol on secondary metabolic path-
ways of RIS like CYP3A4, which can lead to a slight increase of 
C/D of parent compound and/or a competitive effect as both 
drugs are metabolized via the same pathway.
Based upon this data and from a pharmacokinetic point of view, 
it should be taken into account when prescribing amlodipine to an 
ongoing treatment with RIS that the addition leads to changes in C/
Ds. This insight might reveal a comparative disadvantage when 
amlodipine is used as a co-medication. Calcium-channel blockers 
are widely assumed to be a safe and very well tolerable option for 
initial antihypertensive therapy (James et al., 2014); however, 
potential interactions, presumably mediated by the CYP450 path-
way of drug metabolism, have to be considered in order to mini-
mize adverse and/or unwanted effects. Theoretically, beta-blockers 
could be a more favourable choice for treating arterial hyperten-
sion in patients with schizophrenia, taking into account a possible 
underlying adrenergic hyperactivity (Scigliano and Ronchetti, 
2013). Even though we examined only one agent of this pharmaco-
logical class, the focus should be placed on the rather disadvanta-
geous metabolic profile of other compounds such as metoprolol 
which, compared to other beta-blockers, has been shown to 
decrease insulin sensitivity (Ayers et al., 2012; Bakris et al., 2004; 
Phillips et al., 2008). Taking into account the well-known risk 
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factors of patients with severe mental illnesses, this could be a 
less favourable option for the optimal antihypertensive therapy 
regimen.
Limitations
Our sample comprised a large population of naturalistic nature 
and relies on retrospective data. A significant amount of clinical 
parameters (onset and duration of illness, adverse effects, 
comorbidities, duration of drug exposure) were not available. 
Furthermore, there is a large individual variation in sampling 
time as a result of the clinical setting, which may have partially 
accounted for the pronounced inter-individual variation in plasma 
concentrations and metabolic ratios. Besides this large inter-
individual variability in RIS and 9-OH RIS concentrations has 
been already reported in the literature during routine TDM 
(Balant-Gorgia et al., 1999). In the case of multiple plasma con-
centration determinations we minimized the patient bias by 
including only one analysis per patient. Regarding analyses of 
the data, differences in sample characteristics and sample size in 
the three patient groups occurred; thus the comparability of the 
study groups with the control group might be restricted. However, 
in some cases, e.g. regarding the mean age of the different study 
groups, it appeared plausible that patients under antihypertensive 
therapy would be older. Consequently, we avoided stratifying for 
age despite the well-known effect of age on RIS metabolism (Feng 
et al., 2008). Although the size of the control group is remarkably 
bigger, we chose not to reduce our control group taking into 
account the extent of the skewness of the sample distribution.
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